Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology

International Journal of Gynecological Cancer

Volumn 14, Issue 1, 2004, Pages 12-22

  Kim, E Edmund ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gynecologic cancer; PET; PET CT

Indexed keywords

CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; NITROGEN 13; OXYGEN 15; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82;

CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; GYNECOLOGIC CANCER; HUMAN; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; TUMOR BIOPSY; UTERINE CERVIX CANCER; UTERUS SARCOMA; VULVA CANCER;

FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL DISEASES, FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 1442299477     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891x.2004.14224.x     Document Type: Review

References (52)

1. Jemal A, Murray T, Samuels A et al. Cancer Statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Bodurka-Bevers D, Morris M, Eifel PJ et al. Poththerapy surveillance of women with cervical cancer: an outcome analysis. Gynecol Oncol 2000;78:187-93.
3. Zinmy M, Siggelkow W, Schroder W et al. 2-[F-18] fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310-5.
4. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471-86.
5. Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR. Anatometabolic tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993;34:1190-7.
6. Beyer T, Townsend DW, Brun T et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41: 1369-79.
7. Tewson TJ, Krohn KA. PET radiopharmaceuticals: state of the art and future prospects. Semin Nucl Med 1998; 28:221-34.
8. Fowler J, Ding Y-S, Volkow ND. Radiotracers for PET imaging. Semin Nucl Med 2003;28:14-27.
9. Gee MS, Koch CJ, Evans SM et al. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 1999;59:4882-9.
10. Antoch G, Freudenberg LS, Stattaus J et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002;179:1555-60.
11. Dizendorf E, Hany TF, Buck A, von Schulthess GK, Burger C. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003;44:732-8.
12. Chou CY, Chang CH, Yao BL et al. Color Doppler ultrasonography and serum CA125 in the differentiation of benign and malignant ovarian tumors. J Clin Ultrasound 1994;22:491-496.
13. Krag DN. Clinical utility of immunoscintigraphy in managing ovarian cancer. J Nucl Med 1993;34:545-8.
14. Grab D, Flock F, Stohr I, Nussele K. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and position emission tomography. Gynecol Oncol 2000;77:454-9.
15. Hubner KF, McDonald TW, Niethammer JG et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography using 2-[18F]deoxyglucose. Gynecol Oncol 1993;51:197-204.
16. Zimny M, Schroder W, Wolters S et al. 18F-fluorodeoxy-glucose PET in ovarian carcinoma: methodology and preliminary results. Nuklearmedizin 1997;36:228-33.
17. Schroder W, Zimny M, Rudlowski C et al. The role of 18F-fluoro-deoxyglucose positron emission tomography in diagnosis of ovarian cancer. Int J Cancer Oncol 1999;9: 117-22.
18. Romer W, Avril N, Dose J et al. Metabolische charakterisierung von ovarialtumoren mit der positronen-emissions-tomographic and F-18 fluorodeoxyglukose. Fortschr Rontgenstr 1997;166:62-8.
19. Omura GA, Bradhy MF, Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncologic Group experience. J Clin Oncol 1991;9:1138-50.
20. Nakamoto Y, Saga T, Ishimori T et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001;176:1449-54.
21. Holschneider CH, Manuel M, Williams CM et al. FDG-PET in ovarian cancer: use of the standardized uptake value (SUV) to differentiate physiological bowel activity from intraperitoneal metastatic tumor. J Nucl Med 2002;43:29.
22. Ozols RF. Chemotherapy of ovarian cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Updates. Vol. 2, No. 1. Philadelphia: JB Lippincott, 1988, 1-12.
23. Bragg DG, Hricak H. Imaging in gynecologic malignancies. Cancer 1993;71:1648-51.
24. Manuel M, Holschneider CH, Williams CM et al. Correlation of FDG-PET scans with surgicopathologic findings in ovarian cancers. J Nucl Med 2002;43:29.
25. Ak I, Stokkel MPM, Pauwels EKJ. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumors. J Cancer Res Clin Oncol 2000; 126:560-74.
26. Barter J, Baranes W. Second-look laparotomy. In: Rubin S, Sutton G, eds. Ovarian Cancer. New York: McGraw-Hill, 1993, 269-300.
27. Rose PG, Faulhaber P, Miraldi F et al. Positron emission tomography for evaluating a complete clinical response in patients with ovarian cancer. Gynecol Oncol 1994;53: 331-8.
28. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331-8.
29. Zimny M, Siggelkow W, Schroder W et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310-5.
30. Morice P, Sabourin JC, Pautier P et al. Isolated para-aortic node involvement in stage IB/II cervical carcinoma. Eur J Gynaecol Oncol 2000;21:123-5.
31. Hricak H, Yu KK. Radiology in invasive cervical cancer. AJR Am J Roentgenol 1996;167:1101-8.
32. Sugawara Y, Eisbruch A, Kosuda S et al. Evaluation of FDG-PET in patients with cervical cancer. J Nucl Med 1999;40:1125-31.
33. Rose PG, Adler LP, Rodriguez M et al. PET for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999;17:41-5.
34. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001;19:3745-9.
35. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG-PET. Radiology 2001;218:776-82.
36. Smith GT, Hubner KF, McDonald T et al. Cost analysis of FDG-PET for managing patients with ovarian cancer. Clin Pos Imag 1999;2:63-70.
37. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001;39: 883-917.
38. Torizuka T, Nobezawa S, Kanno T et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 2002;29:797-803.
39. Yen R-F, Sun S-S, Shen Y-Y et al. Whole-body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001;21:3691-4.
40. Blodgett TM, Meltzer CC, Townsend DW et al. PET/CT in restaging patients with ovarian carcinoma. J Nucl Med 2002;43:310.
41. Makhija S, Howden N, Edwards R et al. Cost analysis of FDG-PET for managing patients with ovarian cancer. Clin Pos Imag 1999;2:63-70.
42. Lapela M, Leskinen-Kallio S, Varpula M et al. Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med 1995;36:2196-220.
43. Jeong HJ, Chung J-K, Paeng JC et al. Usefulness of 11C methionine PET in the pelvic region for evaluation of recurrent gynecologic cancer in postoperative state. J Nucl Med 2002;43:283.
44. Park DH, Kim KH, Park SY et al. diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography. Korean J Radiol 2000;1:51-5.
45. Sun SS, Chen TC, Yen RF et al. Value of whole-body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2001;21:2957-62.
46. Nakamoto Y, Eisbruch A, Achtyes ED et al. Prognostic value of positron emission tomography using F-18-flurodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol 2002;84:289-95.
47. Pinkus E, Miller TR, Grigsby PW. Improved prognostic value of FDG-PET in patients with cervical cancer using a simple visual analysis of tumor characteristics. J Nucl Med 2002;43:28.
48. Jang HJ, Lee KH, Kim YH et al. The role of FDG-PET for predicting prognosis in squamous cell type uterine cervical carcinoma patients. J Nucl Med 2002;43:28.
49. Nakahara T, Fuji H, Ide M et al. F-18 FDG uptake in endometrial cancer. Clin Nucl Med 2001;26:82-3.
50. Belhocine TZ, Bolle KS, Willems-Foidart J. Usefulness of 18F-FDG-PET in the post-therapy surveillance of endometrial carcinoma. J Nucl Med 2002;43:118-9.
51. Umesaki N, Tanada T, Miyama M et al. Positron emission tomography 18F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001;80:372-7.
52. Cohn DE, Dehdashti F, Gibb RK et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulva cancer. Gynecol Oncol 2002;85:179.